.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP56_SofosbuvirVelpatasvirAnd.SofosbuvirVelpatasvirAnd .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP56_SofosbuvirVelpatasvirAnd.SofosbuvirVelpatasvirAnd| name: | SofosbuvirVelpatasvirAndVoxilaprevir |
| ATC code: | J05AP56 | route: | oral |
| n-compartments | 1 |
A fixed-dose combination of three direct-acting antivirals used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is an HCV NS5B polymerase inhibitor, velpatasvir is an NS5A inhibitor, and voxilaprevir is an NS3/4A protease inhibitor. This combination is approved for use in adults and certain pediatric populations and is marketed as Vosevi.
Pharmacokinetic parameters estimated based on individual PK data from the separate components in healthy adults after oral administration; no published population PK model was identified for the fixed-dose combination in the literature as of 2024-06.